Recent evidence suggests that morbidity and mortality rates for patients with sarcoidosis are rising. In the past 20 years, mortality rates among this population have increased more than 50% among women and 30% among men, with highest mortality rates among African-American women. Additionally, the current use of corticosteroids and other immunosuppressants as first-line therapy for sarcoidosis has significant limitations due to side effects and a lack of evidence as to their long-term effectiveness. A number of novel targeted therapies for a variety of autoimmune inflammatory diseases have recently been approved or are under investigation. These may be the key to unlocking new, more effective therapies for patients with this disease.